Beijing Yongtai Biologics

Yongtai Biologics is a leading Chinese biopharmaceutical company focused on the development of cellular immunotherapy products for the treatment of cancer. The company's core product, EAL, is an autologous activated lymphocyte therapy currently in late-stage clinical trials for the prevention of postsurgical recurrence of liver cancer. Yongtai's pipeline also includes various CAR-T and TCR-T cell therapy candidates targeting both hematological malignancies and solid tumors. With a fully integrated platform covering R&D, clinical trials, and manufacturing, the company aims to address significant unmet medical needs in the oncology space.